None listed
Conditions
Brief summary
Brief description of the study purpose This study aims to evaluate the feasibility of giving platelet (a blood product) transfusions in a patient’s home and the costs, safety and acceptability of the program. Who is it for? You may be eligible for this study if you are male or female, aged 18 or older, diagnosed with haematological malignancy (most commonly Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoma or Myeloma) and requiring platelet transfusions during your treatment. Study details Platelet (blood product) transfusion will be given by nursing staff to select patients with haematological malignancy (blood cancer) in the patient’s own home, instead of in the hospital. This will occur up to 3 times per week for up to 12 weeks. It is hoped that the results from this study will help improves patient comfort, reduces caregiver burden, reduces the use of inpatient hospital beds, and may reduce costs for those requiring blood transfusion.
Interventions
Platelet (blood product) transfusion will be given by nursing staff to select patients with haematological malignancy (blood cancer) in the patient’s own home. This will occur up to 3 times per week for up to 12 weeks and does not affect other treatments the patient may be receiving. The platelet transfusion is the same as standard of care (usually given in the outpatient centre or hospital ward) - 1 unit of platelets given over 15-30 minutes. The platelet transfusion will be given to patients o
Platelet (blood product) transfusion will be given by nursing staff to select patients with haematological malignancy (blood cancer) in the patient’s own home. This will occur up to 3 times per week for up to 12 weeks and does not affect other treatments the patient may be receiving. The platelet transfusion is the same as standard of care (usually given in the outpatient centre or hospital ward) - 1 unit of platelets given over 15-30 minutes. The platelet transfusion will be given to patients on the trial as per the clinical need (based on measured platelet count taken routinely the day prior, or presence of bleeding) and this intervention will be administered at the next clinically appropriate scheduled transfusion.
Sponsors
Monash University
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Age 18 years or over Diagnosis of a haematological malignancy (most commonly Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Lymphoma or Myeloma) Transfusion dependence (currently requiring at least one unit of platelet transfusion per fortnight) Eligible for admission to Hospital in the Home (as per current local guidelines and policies)
Exclusion criteria
Previous severe haemolytic or allergic reactions Unstable cardiorespiratory status (cardiac arrest or myocardial infarction within 12 months, ejection fraction <40%, NYHA class II-IV heart failure) Difficult to obtain intravenous access and does not have an existing or planned central venous access device (CVAD) (e.g. PICC line) No responsible caregiver, inappropriate home environment Treating clinician deems study is not in the best interest of the patient
Outcome results
None listed